검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine Hydrochloride (Gemcitabine Hydrochloride) K-Group, Beta, Inc., a wholly owne…·FRα ORR 0.4% |
|---|---|
Overview Program | Gemcitabine Hydrochloride |
Overview Company | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | HER2 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | From Parenteral to Oral Delivery: Facile Formulation of Oral Gemcitabine Nanospanlastics for Enhanced Bioavailability and Anticancer Activity in Murine Breast Cancer Model.. Gemcitabine hydrochloride (GEM) is a commonly used antineoplastic that is delivered only by intravenous infusion due to its limited oral bioavailability of 10%. The study aims to design and optimize novel Spanlastics (GEM-SLs)… |
Clinical Primary efficacy | ORR 0.4% |
Clinical ORR | 0.4% |
Clinical Result source | ClinicalTrials.gov NCT00942331 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine Hydrochloride (Gemcitabine Hydrochloride) K-Group, Beta, Inc., a wholly owne…·FRα ORR 0.4% |
|---|---|
Overview Program | Gemcitabine Hydrochloride |
Overview Company | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | HER2 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | From Parenteral to Oral Delivery: Facile Formulation of Oral Gemcitabine Nanospanlastics for Enhanced Bioavailability and Anticancer Activity in Murine Breast Cancer Model.. Gemcitabine hydrochloride (GEM) is a commonly used antineoplastic that is delivered only by intravenous infusion due to its limited oral bioavailability of 10%. The study aims to design and optimize novel Spanlastics (GEM-SLs)… |
Clinical Primary efficacy | ORR 0.4% |
Clinical ORR | 0.4% |
Clinical Result source | ClinicalTrials.gov NCT00942331 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교